In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI)

Lancet

Volumn 348, Issue 9040, 1996, Pages 1484-1487

  Wengler, Georg S ^a   Lanfranchi, Arnalda ^b   Frusca, Tiziana ^b   Verardi, Rosanna ^b   Neva, Arabella ^b   Brugnoni, Duilio ^b   Giliani, Silvia ^b   Fiorini, Maurilia ^b   Mella, Patrizia ^b   Guandalini, Fabiola ^b   Mazzolari, Evelina ^b   Pecorelli, Sergio ^b   Notarangelo, Luigi D ^b   Porta, Fulvio ^b   Ugazio, Alberto G ^b  

^a SPEDALI CIVILI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD34 ANTIGEN; CYTOKINE RECEPTOR; HLA DQ ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ARTICLE; B LYMPHOCYTE; CASE REPORT; CAUSE OF DEATH; CESAREAN SECTION; CHIMERA; COMBINED IMMUNODEFICIENCY; FETUS; FETUS ECHOGRAPHY; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; INFECTION; INTRAUTERINE BLOOD TRANSFUSION; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; NEWBORN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

EID: 16144362330     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09392-0     Document Type: Article

References (22)

1. 1 Gelfand EW, Dosch HM. Diagnosis and classification of severe combined immunodeficiency disease. Birth Defects 1983; 19: 65-72.
2. 2 Noguchi M, Yi H, Rosenblatt H, et al. IL-2 Receptor gamma Chain Mutation Results in XSCID in Humans. Cell 1993; 73: 147-57.
3. 3 Clark P, Lester T, Genet S, et al. Screening for mutations causing X-linked severe combined immunodeficiency in the IL-2Rg chain gene by SSCP analysis. Hum Genet 1995; 96: 427-32.
4. 4 Durandy A, Dumez Y, Griscelli C. Diagnostic antenatal des deficits immunitaires hereditaires graves. Arch Fr Pediatr 1985; 42: 163-67.
5. 5 Blau CA, Stamatoyannopoulos G. Preemptive therapy for genetic disease. Nature Med 1996; 2 (2): 161-62.
6. 6 Notarangelo LD, Prati E, Zucca S, et al. Analysis of hematological and immunological parameters in normal fetal blood at 20 weeks of gestational age. Dev Physiopath and Clin 1993; 4: 109-17.
7. 7 Harrison MR, Slotnick RN, Cromblehome TM, Golbus MS, Tarantal AF, Zanjani ED. In-utero transplantation of fetal liver hematopoietic stem cells in monkeys. Lancet 1989; ii: 425-27.
8. 8 Cowan MJ, Tarntal AF, Capper J, Harrison M, Garovoy M. Longterm engraftment following in utero T cell-depleted parental marrow transplantation into fetal rhesus monkeys. Bone Marrow Transplant 1996; 17: 1157-65.
9. 9 Srour EF, Zanjani ED, Cornetta K, et al. Persistence of human multilineage, self-renewing lymphohematopoietic stem cells in chimeric sheep. Blood 1993; 82: 3333-42.
10. 10 Blazar BR, Taylor PA, Vallera DA. Adult bone marrow-derived pluripotent hematopoietic stem cells are engraftable when transferred in utero into moderately anemic fetal recipients. Blood 1995; 85: 833-41.
11. - cell functional capabilities. Blood 1995; 86: 4353-66.
12. 12 Touraine JL, Roncarolo MG, Royo C, Touraine F. Fetal tissue transplantation, BMT and prospective gene therapy in severe immunodeficiencies and enzyme deficiencies. Thymus 1987; 10: 75-87.
13. 13 Slavin S, Naparstek E, Ziegler M, Lewin A. Clinical application of intrauterine BMT for treatment of genetic diseases-feasibility studies. Bone Marrow Transplant 1992; 9: 189-90.
14. 14 Flake AW. Successful treatment of XSCID by in utero transplantation of CD34 entriched paternal bone marrow cells. Blood 1995; 86: 125a.
15. 15 Wengler GS, Allen RC, Parolini O, Smith H, Conley ME. Nonrandom X chromosome inactivation in natural killer cells from obligate carriers of X-linked severe combined immunodeficiency. J Immunol 1993; 150: 700-04.
16. 16 Wengler GS, Notarangelo LD, Berardelli S, Fasth A, Ugazio AG, Parolini D. High prevalence of nonsense, frarne shift, and splice-site mutations in 16 patients with full-blown WAS. Science 1995; 86: 3648-54.
17. 17 Reisner Y, Geha R, Rappeport JM. Reconstitution after transplantation with T lymphocyte depleted HLA haplotype-mismatched bone marrow for SCID. Proc Nat Acad Sci USA 1983; 79: 6047-51.
18. 18 Bordignon C, Notarangelo L, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Nature 1995; 270: 470-75.
19. 19 Mckinnon S, Papadopoulos E, Carabasi M, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of CML after BMT: separation of GvL responses from GvHD. Blood 1995; 86: 1261-68.
20. 20 Vossen JM, vanLeeuwen JE, van Toi MJ, et al. Chimerism and immune reconstitution following allogeneic BMT for SCID. Immunodeficiency 1993; 4: 311-13.
21. 21 Friedrich W, Knobloch C, Greher J, et al. BMT in SCID: Potential and current limitation. Immunodeficiency 1993; 4: 315-22.
22. - stem cells in fetal sheep. Experiment Hematol 1996; 24: 795-806.